AliveDx
- Company typePrivate
- Founded1990
- HeadquartersEysins, Switzerland
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
AliveDx firmographics
Firmographics- Name
- AliveDx
- Legal name
- AliveDx Suisse S.A.
- Website
- https://alivedx.com
- Company type
- Private
- Founded year
- 1990
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Ownership category
- akta.pro rank
AliveDx industry classification
Industry- Product category
- In-Vitro Diagnostics (IVD)
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511), Surgical and Medical Instrument Manufacturing (339112)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Autoimmune, Allergy & Specialized Immunology Diagnostics (HLAHAAAK)
- akta.pro secondary industries
- Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB), Blood Bank, Transfusion Medicine & Immunohematology (HLAHAAAH), Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls) (HLAAAMAL)
Keywords
Where AliveDx is headquartered
LocationHeadquarters
- HQ city
- Eysins
- HQ country
- Switzerland
- HQ region
- Europe
Offices2 records
Markets served
AliveDx business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- MosaiQ Platform and Assays: Sale of the MosaiQ automated multiplex microarray instrument platform along with consumable assay panels (AiPlex CTDplus, AiPlex CD, AiPlex VAS, AiPlex APS, AllergyPlex COMBO). The platform is sold as an instrument with recurring revenue from proprietary microarray consumables and reagents. Revenue model combines hardware instrument sales with recurring consumable reagent revenue.
- Alba Blood Bank Reagents: Sale of manual blood bank reagent products including ABO/RhD antisera, red blood cells, anti-human globulin, rare antisera for extended phenotyping, and enhancement media. The Alba portfolio includes 81 FDA-cleared and 74 CE-marked products sold directly to blood banks, hospitals, and labs globally.
- Alba OEM Products: Supply of intermediate products for blood typing or related applications on an Original Equipment Manufacturer (OEM) basis to other manufacturers and industry partners. Partnering leverages over 30 years of development, manufacturing, and marketing expertise in transfusion diagnostics.
- LumiQ IFA Platform and Consumables: Sale of the LumiQ automated immunofluorescence assay platform and associated reagents. The LumiQ system complements MosaiQ by providing a turnkey solution for autoimmune diagnostics combining screening and identification of autoantibodies.
- Technical Support and Services: Technical support services including evaluation protocols, product usage guidance, and dedicated expert support for Alba products. Service and support offerings include service engineers, application specialists, remote monitoring, and troubleshooting support.
Go-to-market motion4 records
Distribution channels4 records
Marketing channels8 records
AliveDx product offering
Product offeringCore offering
AliveDx designs, manufactures, and sells in-vitro diagnostic instruments and consumable assay panels for autoimmune disease, allergy, and transfusion medicine testing. Its product ecosystem centers on the automated MosaiQ multiplex microarray platform, the LumiQ all-in-one immunofluorescence solution, and the Alba portfolio of manual blood bank reagents. Revenue is generated from instrument sales paired with recurring consumable microarray and reagent sales, supported by technical services and an OEM supply program.
Product overview
AliveDx is an established commercial-stage in-vitro diagnostics company with over 30 years of experience, offering a unified portfolio of automated and manual diagnostic solutions. The core product ecosystem centers on three main platforms: MosaiQ (fully automated high-throughput multiplex microarray platform), LumiQ (all-in-one immunofluorescence assay solution), and Alba (manual blood bank reagents). The MosaiQ platform serves as the primary automated testing system, with specialized assay modules including AiPlex CTDplus (Connective Tissue Diseases), AiPlex CD (Celiac Disease), AiPlex VAS (Vasculitis), AiPlex APS (Antiphospholipid Syndrome), and AllergyPlex COMBO (Allergy testing). The Alba line provides manual blood bank reagents including antisera, red blood cells, and enhancement media, complemented by OEM solutions and technical support services. This integrated approach enables testing across autoimmune diseases, allergies, and immunohematology applications.
Differentiator
Problem solved
Functional benefit
Brands
- MosaiQ: Fully automated high-throughput platform for multiplex testing of autoimmune diseases and allergies using advanced microarray technology.
- LumiQ
- Alba
- AiPlex
Products and services
- MosaiQ Platform
- LumiQ
- Alba Blood Bank Reagents
- MosaiQ AiPlex CTDplus Assay
- MosaiQ AiPlex CD Assay
- MosaiQ AiPlex VAS Assay
- AllergyPlex COMBO Assay
- Alba Elution Kit
- Alba OEM Solutions
- Alba Quotient Services
Quantifiable outcome
- Up to 28501 multiplexed results per hour (largest panel under development - AllergyPlex COMBO)
- +5 more outcomes
Companies that use AliveDx
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles3 records
AliveDx technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability5 records
Feature6 records
AliveDx partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core.
- Ilex MedicalcoreAliveDx Suisse S.A. signed a strategic distribution agreement with Ilex Medical authorizing the distribution of MosaiQ and LumiQ solutions in Israel. This partnership represents an important milestone in AliveDx's strategy to expand its footprint in key markets and support healthcare providers with innovative diagnostic technologies.
- Hospital Supply Corporation (HSC)coreAliveDx Suisse S.A. signed a strategic distribution agreement with Hospital Supply Corporation (HSC), Pakistan. HSC is authorized to distribute AliveDx's MosaiQ and LumiQ solutions across Pakistan. This partnership represents an important milestone in AliveDx's expansion in South Asia and reinforces its commitment to working with established local partners to deliver innovative, high-value diagnostic technologies.
- Address MedicalcoreAliveDx Suisse S.A. signed a strategic distribution agreement with Address Medical authorizing the distribution of MosaiQ and LumiQ solutions in United Arab Emirates. This partnership represents another important milestone in AliveDx's strategy to expand its footprint in key emerging markets and support healthcare providers with innovative diagnostic technologies.
- DPC Lebanon (Diagnostic Products Corporation Lebanon Sarl)coreAliveDx Suisse S.A. signed a strategic distribution agreement with DPC Lebanon authorizing the distribution of MosaiQ and LumiQ solutions across Lebanon. This partnership represents an important milestone in AliveDx's expansion in the Middle East through established local partners.
- Reacting SarlcoreAliveDx Suisse S.A. signed a strategic distribution agreement with Reacting Sarl authorizing the distribution of MosaiQ and LumiQ solutions across Morocco. This partnership represents a further step in AliveDx's expansion across North Africa and underscores its commitment to working with strong local partners to deliver innovative diagnostic technologies.
- Medipac Technologies LtdcoreAliveDx signed a strategic distribution agreement with Medipac Technologies Ltd, a leading healthcare-solutions provider in Bangladesh. Medipac Technologies Ltd distributes AliveDx's MosaiQ and LumiQ diagnostic platforms across Bangladesh, effective immediately. This collaboration strengthens AliveDx's commitment to expanding its presence in high-growth emerging markets.
- TransmediccoreAliveDx Suisse S.A. and Transmedic Indonesia, Thailand, and Singapore signed a second distribution agreement enabling Transmedic to distribute the LumiQ solution across these markets in addition to the MosaiQ platform from the first agreement. This partnership underscores AliveDx's dedication to expanding its global footprint and delivering clinical and economic value to clinicians.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
AliveDx competitors and assessment
Company assessmentBroad incumbents
- Roche Diagnostics: Roche cobas immunoassay systems include autoimmune and infectious disease testing serving the same hospital and reference laboratory customers. Roche is a much larger broad-line incumbent that competes in multiplex autoimmune disease diagnostics.
- Siemens Healthineers: Siemens Healthineers offers ADVIA Centaur, Atellica, and other immunoassay platforms for infectious disease, autoimmune, and allergy testing. It is a broad-line incumbent rather than an autoimmune/allergy specialist.
- Ortho Clinical Diagnostics: Ortho Clinical Diagnostics is a major player in transfusion medicine and immunohematology, directly competing with AliveDx's Alba blood bank reagents. It is a broader incumbent in blood bank diagnostics rather than a focused autoimmune specialist.
- Abbott Diagnostics: Abbott Diagnostics is a broad IVD incumbent with ARCHITECT and Alinity immunoassay systems that overlap with autoimmune and allergy testing menus. It is a much larger player and offers broader diagnostics portfolios rather than specializing in multiplex autoimmune and allergy testing.
Direct peers
- BIO-RAD Laboratories: BIO-RAD competes in autoimmune multiplex diagnostics (BioPlex 2200) and is a major supplier of immunohematology and blood bank reagents. Its product, customer base, and dual autoimmune + blood bank focus closely mirror AliveDx's portfolio.
- Bühlmann Laboratories: Bühlmann is a Swiss specialty diagnostics company focused on autoimmune and inflammatory disease testing, including calprotectin and celiac assays. It is comparable as a similarly-sized niche immunology vendor targeting clinical laboratories.
- Thermo Fisher Scientific (Phadia / ImmunoCAP): Phadia, the immunoassay arm of Thermo Fisher, is the market leader in allergy diagnostics with ImmunoCAP and competes in autoimmune diagnostics. It is the most direct competitor to AliveDx's MosaiQ and LumiQ platforms and serves the same hospital and reference laboratory customers.
- AESKU Group: AESKU specializes in autoimmune diagnostics including IFA, ELISA, and immunoblot products for the same clinical laboratory customers as AliveDx. It is similarly specialized in autoimmune and offers comparable technology approaches.
- EUROIMMUN (PerkinElmer / Revvity): EUROIMMUN is a leader in autoimmune diagnostics with a broad IFA, ELISA, and microarray menu. It serves the same clinical laboratory and hospital customer base with comparable autoimmune disease test panels and is acquired by Revvity (formerly PerkinElmer).
Emerging players
- Fujirebio: Fujirebio is a specialty diagnostics player with focus on autoimmune, infectious disease, and oncology assays. It is comparable as a specialty immunoassay vendor targeting overlapping clinical lab segments, though with a narrower multiplex microarray focus than AliveDx.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
AliveDx social profiles
Digital presenceAliveDx compliance and trust
Trust signalCompliance4 records
AliveDx financial estimates
Financial estimateRevenue estimate
Valuation estimate
AliveDx leadership team
Management profileNumber of profiles
Profiles13 records
AliveDx funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AliveDx M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AliveDx
What does AliveDx do?
AliveDx designs, manufactures, and sells in-vitro diagnostic instruments and consumable assay panels for autoimmune disease, allergy, and transfusion medicine testing. Its product ecosystem centers on the automated MosaiQ multiplex microarray platform, the LumiQ all-in-one immunofluorescence solution, and the Alba portfolio of manual blood bank reagents. Revenue is generated from instrument sales paired with recurring consumable microarray and reagent sales, supported by technical services and an OEM supply program.
Is AliveDx a public or private company?
AliveDx is a private company. It is classified as unknown and is currently operating.
When was AliveDx founded?
AliveDx was founded in 1990. It employs 251 to 500 people.
Where is AliveDx based?
AliveDx is headquartered in Eysins, Switzerland, in the Europe region.
How does AliveDx make money?
Five revenue lines are on record. MosaiQ Platform and Assays are the primary driver. The others are alba Blood Bank Reagents, alba OEM Products, lumiQ IFA Platform and Consumables and technical Support and Services.
Who are AliveDx's main competitors?
Broad incumbents on record are Roche Diagnostics, Siemens Healthineers, Ortho Clinical Diagnostics and Abbott Diagnostics. Direct peers are BIO-RAD Laboratories, Bühlmann Laboratories, Thermo Fisher Scientific (Phadia / ImmunoCAP), AESKU Group and EUROIMMUN (PerkinElmer / Revvity). Fujirebio is listed as an emerging player.
Does AliveDx have an API?
No public API is recorded for AliveDx.
What industry is AliveDx in?
AliveDx's product category is In-Vitro Diagnostics (IVD). Its primary akta.pro industry code is HLAHAAAK, Autoimmune, Allergy & Specialized Immunology Diagnostics, with a secondary code of HLAGAEAB, Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry). Its NAICS code is 325413 and its SIC code is 2835.